PCNS-DLBCL is a rare extranodal non-Hodgkin lymphoma that primarily affects the brain, spine, or vitreoretinal space. The prognosis for PCNS-DLBCL is significantly worse than that for its systemic counterpart. Understanding how and where this tumor initiates, and how it survives or depends on the microenvironment of the CNS is key to understanding the underlying biology and identifying reliable biomarkers for selecting personalized therapy or for biologically directed therapy that could improve the cure rate of CNS lymphomas.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Prevalence of non-GC phenotype
Timeframe: 12 months: from the end of samples collection to the end of study analysis
Prevalence of mutations, copy number abnormalities, and structural variants
Timeframe: 12 months: from the end of samples collection to the end of study analysis
Prevalence of PCNS-DLBCL molecular subtypes defined by genetic lesions
Timeframe: 12 months: from the end of samples collection to the end of study analysis
Prevalence of PCNS-DLBCL molecular subtypes defined by gene expression signatures
Timeframe: 12 months: from the end of samples collection to the end of study analysis
Prevalence of PCNS-DLBCL molecular subtypes defined by genetic methylation profile
Timeframe: 12 months: from the end of samples collection to the end of study analysis
International Extranodal Lymphoma Study Group - IELSG